Background: Rheumatic heart disease (RHD), concomitant to valvular damage, heart failure, arrhythmias and pulmonary hypertension is the major source of cardiovascular morbidity and mortality in the young, predominantly in low- and middle-income countries (LMICs). We investigated the association of valve lesions in RHD with cardiovascular magnetic resonance (CMR) tissue characteristics and autophagy markers, in this study. Methods: Forty-seven (47) patients (42 ± 12.8 years), with advanced RHD, awaiting valve replacement, confirmed on echocardiography, and matched with 30 healthy controls (39 ± 12.1 years), were scanned using a 3T Siemens Magnetom Skyra. CMR parameters were derived from the following acquisitions: cine imaging of the short and long axes, T1 mapping (MOLLI, 5(3)3, estimation of ECV and late gadolinium enhancement (LGE) imaging. For the cellular study, we analysed the immunoexpression of Beclin, LC3, p62, BAX, Bcl-2 and caspase-3 in patients confirmed with RHD and valvular heart disease

Introduction. Aortic stenosis is characterised both by progressive narrowing of the valve and the hypertrophic response of the left ventricle. The purpose of this thesis was to study the contribution of inflammation and calcification to valve narrowing using Positron Emission and Computed Tomography (PET/CT) and to investigate the hypertrophic response using cardiovascular magnetic resonance (CMR). Methods. PET/CT studies. Patients with aortic sclerosis and mild, moderate and severe stenosis were prospectively compared to matched control subjects. Aortic valve severity was determined by echocardiography. Calcification and inflammation in the aortic valve and coronary arteries were assessed by sodium 18-­‐fluoride (18F-­‐NaF) and 18-­‐fluorodeoxyglucose (18F-­‐FDG) uptake using PET. CMR studies. Consecutive patients with moderate or severe aortic stenosis undergoing CMR were enrolled into a registry. Patients who received gadolinium contrast were categorised into absent, mid-­‐ wall or infarct patterns of late gadolinium enhancement (LGE) by blinded independent observers. Patients follow-­‐up was completed using patient questionnaires, source record data and the National Strategic Tracing Scheme. After excluding those patients with concomitant triggers to LV remodeling, the extent and patterns of hypertrophy were investigated based upon measurements of indexed LV mass, indexed LV volume and the relative wall mass. Results. PET/CT studies. 121 subjects (20 controls; 20 aortic sclerosis; 25 mild, 33 moderate and 23 severe aortic stenosis) were studied. Quantification of tracer uptake within the valve demonstrated excellent inter-­‐observer reproducibility with no biases and limits of agreement of ±0.21 (18F-­‐NaF) and ±0.13 (18F-­‐FDG) for maximum tissue-­‐to-­‐background ratios (TBR). Activity of both tracers was higher in patients with aortic stenosis than control subjects (18F-­‐NaF: 2.87±0.82 vs 1.55±0.17; 18F-­‐ FDG: 1.58±0.21 vs 1.30±0.13; both P<0.001). 18F-­‐NaF uptake displayed a progressive rise with valve severity (r2=0.540, P<0.001) with a more modest increase observed for 18F-­‐FDG (r2=0.218; P<0.001). Amongst patients with aortic stenosis, 91% had increased 18F-­‐NaF (>1.97) and 35% increased 18F-­‐ FDG (>1.63) uptake. Increased 18F-­‐NaF uptake was also observed in the coronary arteries in a subset of patients with atherosclerosis. These patients (n=40) had higher rates of prior cardiovascular events (p=0.016) and angina (p=0.023), and higher Framingham risk scores (p=0.011). CMR studies. 143 patients (aged 68±14 years; 97 male) were followed up for 2.0±1.4 years and 27 died. Compared to those with no LGE (n=49), univariate analysis revealed that patients with mid-­‐wall fibrosis (n=54) had an eight-­‐fold increase in all-­‐cause mortality despite similar aortic stenosis severity and coronary artery disease burden. Patients with an infarct pattern (n=40) had a six-­‐fold increase. Mid-­‐wall fibrosis (HR 5.35 [95% CI 1.16-­‐24.56]; P=0.03) emerged as an independent predictor of all cause mortality by multivariate analysis. The pattern of LV remodelling was studied in 91 patients (61±21 years; 57 male) and displayed wide variation comprising normal ventricular geometry (n=11), concentric remodelling (n=11), asymmetric remodelling (n=11), concentric hypertrophy (n=34), asymmetric hypertrophy (n=14) and LV decompensation (n=10). The magnitude of the hypertrophic response was unrelated to the severity of aortic valve narrowing. Conclusions. Modern imaging techniques have provided important insights in to the pathology underlying aortic stenosis and suggest that valvular calcification and myocardial fibrosis have a key role. Both represent important potential targets for future therapeutic interventions.

Marfan syndrome (MFS) is the commonest inherited disorder of connective tissue and is associated with a high risk of potentially life-threatening complications, including aortic aneurysm, dissection and rupture, and, perhaps, ventricular disease. This work describes the prospective application of advanced cardiovascular magnetic resonance techniques to the aorta and heart of consecutive, unselected subjects with MFS, and to appropriately matched control populations. Comprehensive 3D visualisation of blood flow in the entire thoracic aorta of subjects with MFS was achieved using a time-resolved phase-contrast magnetic resonance technique with 3-directional velocity encoding (4D flow), demonstrating a high prevalence of major flow disturbance (87 ± 12%), compared to controls (28 ±18%), localising to those regions of the aorta known to be most prone to aortic dissection (sinuses of Valsalva and proximal descending aorta). Wall shear stress, recently identified as a potentially important determinant of aneurysm progression and rupture, was interrogated in these datasets at the sinuses of Valsalva (SOV), ascending aorta (AA), arch, and proximal (PDA) and distal descending aorta (DDA), using the 4D flow datasets, and was shown to be significantly reduced at each location (SOV -15%; AA -12%; Arch -17%; PDA -18%; and DDA -14%, p<0.05 for each), in subjects with MFS compared to healthy subjects. 4D flow datasets were used to generate relative pressure maps in healthy subjects and in subjects with several aortic diseases. A novel method for the separate evaluation of the components of relative pressure was applied, revealing marked differences in the relative contribution of the components of pressure (unsteady > convective >> viscous), and characteristic differences between subjects in overall relative pressure, and its components. Left ventricular volumes and function were evaluated in subjects with MFS, and did not differ significantly from healthy subjects in the absence of significant valvular regurgitation and / or shunt. Left ventricular end-diastolic volume varied markedly with degree of regurgitation (r=0.75, p=0.0001). The mechanistic implications of these findings, and the potential role of these techniques in the evaluation of cardiovascular disease, are discussed.

No description available.

BACKGROUND Aortic stenosis affects not only the valve but also the myocardium. In response to the increased afterload, left ventricular hypertrophy initially occurs as a compensatory response to maintain wall stress and cardiac output but ultimately, decompensation and heart failure ensues. The transition from adaptation to decompensation is driven by myocyte death and myocardial fibrosis. The aims of the thesis are to investigate cardiovascular magnetic resonance assessment of disease severity and myocardial fibrosis, and explore its relationship with other biomarkers of disease activity and clinical outcome in patients with aortic stenosis. METHODS AND RESULTS The conventional assessment of aortic stenosis relies heavily on two-dimensional and Doppler echocardiography but there are inherent limitations in echocardiography that can affect the severity classification. I demonstrated that cardiovascular magnetic resonance offered a more accurate estimation of left ventricular volumes and mass, and excellent myocardial characterization. Indeed, inaccurate stroke volume estimation by Doppler echocardiography and inconsistent thresholds in current guidelines accounted for more than 40% of patients with discordant small-area, lowgradient aortic stenosis. These data may explain the variable prognosis reported in this unique group of patients, and argue for more accurate assessment of borderline cases with cardiovascular magnetic resonance. Late gadolinium enhancement imaging detects focal areas of established myocardial fibrosis. In many conditions, including aortic stenosis, a more diffuse form of fibrosis predominates, which is potentially reversible and not readily identified by late gadolinium enhancement. Recently several myocardial T1 mapping approaches have been developed to quantify diffuse fibrosis. Using a standardized and systematic approach, I compared several commonly used T1 mapping techniques and identified that extracellular volume had the best profile (reproducibility and discriminatory potential) for the identification of diffuse fibrosis in patients with aortic stenosis. Cardiac troponin is a structural protein present in the cardiac myocytes. Recent advances in assay technology have substantially improved sensitivity, allowing quantification of troponin concentrations with a high degree of precision in everyone. In more than 250 patients with aortic stenosis, I demonstrated that cardiac troponin I concentrations were independently associated with markers of left ventricular decompensation (hypertrophy and fibrosis) and predicted clinical outcome in patients with aortic stenosis. This suggests that myocardial fibrosis detected by cardiovascular magnetic resonance is consequent on myocardial injury secondary to left ventricular decompensation. Left ventricular hypertrophy with strain pattern on a 12-lead electrocardiogram is associated with poor outcome in patients with aortic stenosis, but the mechanism of this electrocardiographic pattern has not been described. In more than 300 patients with aortic stenosis, I demonstrated that these characteristic repolarization abnormalities were a highly specific marker of focal mid-wall myocardial fibrosis (specificity of 99% and sensitivity of 54%). Moreover, the prognostic value of this electrocardiographic pattern was again confirmed with markedly worse long-term outcomes in these patients. CONCLUSION I have demonstrated that cardiovascular magnetic resonance can assist in the assessment of disease severity in patients with aortic stenosis and discordant echocardiographic findings. Moreover, I have validated the assessment of diffuse myocardial fibrosis, as well as, demonstrated the close association between myocardial fibrosis and biomarkers of myocardial injury and electrocardiographic strain pattern that predicted an adverse outcome in patients with aortic stenosis.

BACKGROUND: The abnormal signal intensity in cardiac T₂-weighted images is associated with various pathologies including myocardial edema. However, the assessment of pathologies based on signal intensity is affected by the acquisition parameters and the sensitivities of the receiver coils. T₂ mapping has been proposed to overcome limitations of T₂-weighted imaging, but most methods are limited in spatial and/or temporal resolution. Here we present and evaluate a double inversion recovery radial fast spin-echo (DIR-RADFSE) technique that yields data with high spatiotemporal resolution for cardiac T₂ mapping. METHODS: DIR-RADFSE data were collected at 1.5 T on phantoms and subjects with echo train length (ETL) = 16, receiver bandwidth (BW) = +/-32 kHz, TR = 1RR, matrix size = 256 x 256. Since only 16 views per echo time (TE) are collected, two algorithms designed to reconstruct highly undersampled radial data were used to generate images for 16 time points: the Echo-Sharing (ES) and the CUrve Reconstruction via pca-based Linearization with Indirect Echo compensation (CURLIE) algorithm. T₂ maps were generated via least-squares fitting or the Slice-resolved Extended Phase Graph (SEPG) model fitting. The CURLIE-SEPG algorithm accounts for the effect of indirect echoes. The algorithms were compared based on reproducibility, using Bland-Altman analysis on data from 7 healthy volunteers, and T₂ accuracy (against a single-echo spin-echo technique) using phantoms. RESULTS: Both reconstruction algorithms generated in vivo images with high spatiotemporal resolution and showed good reproducibility. Mean T₂ difference between repeated measures and the coefficient of repeatability were 0.58 ms and 2.97 for ES and 0.09 ms and 4.85 for CURLIE-SEPG. In vivo T₂ estimates from ES were higher than those from CURLIE-SEPG. In phantoms, CURLIE-SEPG yielded more accurate T₂s compared to reference values (error was 7.5-13.9% for ES and 0.6-2.1% for CURLIE-SEPG), consistent with the fact that CURLIE-SEPG compensates for the effects of indirect echoes. The potential of T₂ mapping with CURLIE-SEPG is demonstrated in two subjects with known heart disease. Elevated T₂ values were observed in areas of suspected pathology. CONCLUSIONS: DIR-RADFSE yielded TE images with high spatiotemporal resolution. Two algorithms for generating T₂ maps from highly undersampled data were evaluated in terms of accuracy and reproducibility. Results showed that CURLIE-SEPG yields T₂ estimates that are reproducible and more accurate than ES.

Both hypertrophied and failing hearts are characterised by pathological left ventricular (LV) remodelling, impaired myocardial energy status and alteration in substrate metabolism. Cardiac magnetic resonance imaging (CMR) and magnetic resonance spectroscopy (MRS) are powerful tools in the characterisation of these disease conditions. More recent techniques have allowed assessment of myocardial steatosis using ¹H-MRS and tissue oxygenation using blood oxygen level dependent (BOLD) CMR. In hypertrophy and heart failure, studies on steatosis and the relationship with other parameters such as myocardial function and fibrosis, especially in humans are limited. I therefore investigated the presence of steatosis in severe aortic stenosis (AS) and dilated cardiomyopathy (DCM), and further assessed its relation to contractile function. This study found that myocardial triglyceride (TG) content is increased in both symptomatic and asymptomatic AS patients (lipid/water ratio 0.89±0.42% in symptomatic AS; 0.75±0.36% in asymptomatic AS vs. controls 0.45±0.17%, both p<0.05) and DCM patients (lipid/ratio 0.64±0.44% vs. controls 0.40±0.13%, p=0.03). Circumferential strain was lower in both AS (-16.4±2.5% in symptomatic AS; -18.9±2.9% in asymptomatic AS vs. controls 20.7±2.0%, both p<0.05) and DCM patients (-12.3±3.4% vs. controls -20.9±1.7%, p<0.001). In AS, myocardial contractility is related to the degree of steatosis, and were both reversible following aortic valve replacement (AVR), lipid/water ratio 0.92±0.41% vs. pre AVR 0.45±0.17%, p=0.04 and circumferential strain -17.2±2.0% vs. pre AVR -19.5±3.2%, p=0.04. A novel finding of this study was significant correlation of MRS-measured TG content with histological staining of TG of the myocardium, taken from endomyocardial biopsy during AVR. In DCM, myocardial TG was independently associated with LV dilatation and correlated significantly with hepatic TG, which suggests that both cardiac and hepatic steatosis might be a common feature in the failing heart. Additionally, although the hypertrophied heart is characterised by impaired perfusion, it is unknown if this is severe enough to translate into tissue deoxygenation and ischaemia. I assessed this by using adenosine vasodilator stress test and BOLD-CMR in patients with severe AS. It was found that AS patients had reduced perfusion (myocardial perfusion reserve index-MPRI 1.0±0.3 vs. controls 1.7±0.3, p<0.001), and blunted tissue oxygenation (blood-oxygen level dependent-BOLD signal intensity-SI change 4.8±9.6% vs. controls 18.2±11.6%, p=0.001) during stress. Importantly, there was a substantial improvement in perfusion and oxygenation towards normal after AVR, MPRI 1.5±0.4, p=0.005 vs. pre AVR and BOLD SI change 16.4±7.0%, p=0.014 vs. pre AVR. Overall, the work in this thesis supports the powerful role of CMR in assessing LV function and elucidating metabolic mechanisms in the hypertrophied and failing heart.

Inflammatory arthropathies and systemic rheumatic diseases (IASRDs) commonly involve the cardiovascular system, and are associated with high morbidity and mortality. Mechanisms of cardiovascular involvement in these clinical entities are not fully understood. Cardiovascular magnetic resonance (CMR) is the single imaging modality capable of assessing non-invasively cardiac function, strain, ischaemia, altered vascular function, perfusion, oedema/inflammation and fibrosis. Furthermore, magnetic resonance spectroscopy (MRS) can give further insights into the status of myocardial energetics and lipidosis. The pathophysiological mechanisms and phenotype of cardiovascular disease (CVD) in IASRDs need further clarification. CMR is an ideal tool for the early identification and monitoring of cardiac manifestations in patients with IASRDs. Hence, the aims of this D.Phil project were to (i) utilise CMR and MRS to study disease mechanisms in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), and (ii) to assess the role of anti-cytokine therapies in abrogation of cardiovascular complications and effects on cardiovascular function in patients with RA, ankylosing spondylitis (AS) and psoriatic arthritis (PsA). First, we used CMR to assess myocardial structure and function in RA, SLE and SSc patients with no known cardiovascular symptoms. Patients and controls were stratified by the presence of traditional cardiovascular risk factors (CVRFs). Our data demonstrated no differences in overall left ventricular (LV) systolic function, size and mass between patients and matched controls. There were, however, impairments in regional function and myocardial deformation, which is most severe in RA, SLE and SSc patients with CVRFs. We also found evidence of impaired vascular function in RA, SLE and SSc, using pulse wave velocity (PWV) and aortic distensibility, and again, showed that patients with CVRFs demonstrated the most severe aberrations, while patients without CVRFs and controls with CVRFs had an intermediate phenotype. Abnormalities in vascular and regional function were most severe in patients with SSc. Also, we showed that impaired vascular function correlated with abnormal systolic myocardial strain and diastolic strain rate in all groups of IASRDs studied. These data have implications for the clinical care of patients with RA, SLE and SSc and show that there is extensive cardiovascular involvement in asymptomatic patients. These results also suggest that early identification and stratification of CVD in IASRDs, with non-invasive techniques like CMR, may permit earlier intervention, thus potentially reducing the effect of CVD on morbidity and mortality in IASRDs. Lastly, these data highlight the importance of early detection and aggressive management of co-existent traditional CVRFs, as they confer incremental risk of CVD in patients with IASRDs. Second, we used CMR for comprehensive phenotyping of tissue characteristics in patients with RA, SLE and SSc. Our data confirmed that subclinical myocardial changes are common in patients with IASRDs (even with apparently normal hearts), which can be detected using multiparametric CMR. In addition to focal areas of fibrosis (detected by late gadolinium enhancement [LGE]), there were also areas of focal myocardial oedema or inflammation (detected by T2-weighted imaging). Further, using more sensitive techniques such as native T1 mapping and extracellular volume (ECV) quantification, we were able to demonstrate even more areas of myocardial involvement in IASRD patients than conventional CMR techniques can reveal, with patients showing significantly larger areas of T1 abnormality and expanded ECV, which likely represent a combination of low grade inflammation and diffuse myocardial fibrosis that are well-described disease processes in this cohort. We also found that T1 and ECV measures were associated with subtle myocardial systolic and diastolic dysfunction. The results of this study suggest that CMR, particularly T1 and ECV quantification, can be used for early detection of subclinical myocardial involvement in IASRD patients, potentially serving as an early screening tool before overt LV dysfunction or irreversible myocardial damage occurs. Third, we utilised CMR to study myocardial perfusion in patients with RA, SLE and SSc. We found that myocardial perfusion was impaired in asymptomatic IASRD with no overt heart disease. Non-segmental, subendocardial perfusion defects consistent with microvascular dysfunction were present in 47%, 31% and 41% of RA, SLE and SSc patients, respectively. Furthermore, there was a significant correlation between MPRI and systolic and diastolic regional function in all groups of patients. In RA and SSc, there was also a correlation between myocardial perfusion reserve index (MPRI) and disease activity. SSc patients had the greatest burden of ECV expansion, and in this group ECV also correlated with MPRI. These data led us to hypothesise that myocardial ischaemia likely leads to impaired myocardial relaxation and diffuse fibrosis, which predate overt dysfunction in contractility. Fourth, we investigated the effect of TNF-alpha inhibitors on myocardial and vascular function and structure in RA, AS and PsA patients. We confirmed that anti-TNF therapy was associated with improvements in serum inflammatory parameters like CRP and ESR, as well as with improved clinical measures of disease activity. Anti-TNF therapy, however, was not related to a change in left ventricular size, mass and global systolic function. We found that inhibition of TNF-alpha activity does result in better myocardial strain and strain rate, likely reflecting an improvement in myocardial inflammatory burden. Moreover, these findings were also supported by improvements in T2 weighted measures, native T1 values and ECV calculations. There was, however, no significant change in myocardial perfusion following anti-TNF therapy. These results support the hypothesis that during episodes of disease activity, myocardial oedema is present in patients with IASRDS and that by reducing the systemic inflammatory response, improvements in myocardial and vascular function can be achieved. Finally, we used CMR and MRS in asymptomatic RA and SLE patients (with normal hearts on echocardiography) to investigate cardiac metabolic status in this cohort. We found that myocardial energetics were impaired in patients, despite preserved overall ejection fraction. Interestingly, abnormal myocardial energetics were associated with presence of LGE, decreased myocardial perfusion, expanded ECV, volume fraction of T1 >990ms (which represents >2 standard deviations above the mean T1 value at 1.5T) and left atrial size. We did not find any difference in myocardial and hepatic lipid content between patients and controls. These data clearly demonstrate that abnormalities in cardiac energetics are present in IASRD patients even before the development of overt cardiac dysfunction, and may be driven by microvascular function and fibrosis.

No description available.

Background: Resistant hypertension (RH) is defined as blood pressure (BP) that remains elevated (>140/90mmHg) despite being treated with an antihypertensive regimen of 3 or more medications from different classes, including a long-acting calcium channel blocker, an angiotensin converting enzyme inhibitor or angiotension receptor blocker and a diuretic. The prevalence of RH in South Africa is currently unknown, however, clinical reports suggest that it is not rare. Patients with RH are significantly predisposed to cardiovascular (CV) diseases compared to patients with controlled BP. Consequences of RH include left ventricular hypertrophy, heart failure, ischaemic heart disease, chronic kidney disease leading to end-stage renal disease, stroke, vascular dementia, CV death and peripheral arterial disease. A proportion of patients with RH who never achieve BP control despite maximal medical treatment, represent a potentially novel and distinctive phenotype which is different from RH patients whose BP canbe controlled. Recognising and categorising such patients becomes the initial and crucial step in stratifying phenotypes and defining mechanisms of treatment resistance. Objectives: The aim of this study was to identify patients with resistant uncontrolled hypertension (RUH) and compare phenotypes in these patients to resistant controlled hypertensives (RCH). Methods: We enrolled 50 patients from the Groote Schuur Hospital Hypertension Clinic: a teriary referral hospital for RH. Patients on 4 or more antihypertensive medication including a diuretic, with BP< 140/90mmHg were considered RCH, and those with BP ≥ 140/90 considered RUH. Assessments included clinical examination, electrocardiography, echocardiography, applanation tonometry, serum biomarkers and cardiovascular magnetic resonance (CMR - which included biventricular volumes and function, myocardial strain, tissue characteristics and late gadolinium enhancement - LGE). Results: Thirty were diagnosed with RUH and twenty with RCH. Patients with RUH were more likely to have a longer duration since diagnosis of hypertension (10.5±10.7 vs. 3.6±3.4, p=0.02) and more likely to be on treatment that included an ACE-inhibitor (90% vs. 58%, p=0.01). As expected, patients with RUH had significantly higher systolic BP (155.6±21.6 vs. 137.8±16.5 mmHg, p< 0.001), diastolic BP (88.4±14.5 vs. 77.5±13.6 mmHg, p= 0.03), mean arterial BP (115.4±17.2 vs 101±15.3 mmHg, p= 0.004) and pulse pressure (67.3±14.2 vs. 60.1±12.4 mmHg, p=0.001). Further, RUH patients had significantly lower large artery elasticity (12.5±4 vs 14.7±3.8ml/mmHgx100, p=0.08) and lower small artery elasticity (4.1±2.1 vs. 6.9±3.6ml/mmHgx100, p< 0.001). RUH patients also had a higher systemic vascular resistance (1754±418.4 vs. 1363±371.5dyneXsecXcm-5, p=0.002). On CMR, RUH patients had lower right ventricular (RV) end-systolic and end-diastolic volumes (p=0.02), as well as higher indexed left ventricular mass (LVMI) (61.6±17.6 vs 52.9±13.9 g/m2 , p= 0.06). There were no differences in native T1, extracellular volume quantification and LGE volume fraction between RUH and RCH patients. Conclusions: Patients with RUH have a greater involvement and more severe CV phenotype, that is likely to result in increased CV morbidity and mortality, including greater target end organ damage as a result of vascular adaptations and concentric remodeling.